NK Cell Differentiation via Adipocyte Co-Culture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating NK cells from stem cells, such as iPSCs and ADSCs, face challenges including the loss of NK cells during separation from undifferentiated iPSCs and the inefficiency of differentiation processes, which can result in reduced anti-tumor activity.
Innovation Solution
The method involves co-culturing non-fully differentiated stem cells with adipocyte-isolated NK cells to achieve a high efficiency of differentiation into clinically safe NK cells, with the goal of achieving at least 60% to 90% differentiation and maintaining similar anti-tumor activity to endogenous NK cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If iPSCs are used to generate NK cells, then there is no immune rejection response, but undifferentiated iPSCs may differentiate into cancer cells in the patient's body
Solution Approach 1:
The patent extracts and removes undifferentiated iPSCs from the NK cell population through separation processes (such as flow cytometry or magnetic sorting) based on surface marker differences. This extraction eliminates the tumorigenic risk while preserving the anti-tumor activity of the differentiated NK cells, directly resolving the contradiction between immune compatibility and cancer risk.
Solution Approach 2:
The patent introduces intermediary separation media and techniques (flow cytometry, magnetic beads, cell sorting devices) that act as mediators between the iPSC-derived cell population and the final therapeutic NK cell product. These intermediaries enable selective enrichment of differentiated NK cells while removing undifferentiated cells, solving the contradiction without compromising the patient-specific immune compatibility.
2Reliability
If NK cells are completely separated from undifferentiated iPSCs, then tumorigenicity is reduced, but a large amount of NK cells are lost during separation
Solution Approach 1:
The patent segments the separation process into multiple stages (e.g., initial enrichment, intermediate sorting, final purification) using different separation techniques at each stage. This segmentation allows progressive enrichment of NK cells while minimizing loss at any single step, achieving high purity with reduced overall cell loss compared to a single harsh separation step.
Solution Approach 2:
The patent utilizes parameter changes in separation conditions (such as adjusting flow rates, magnetic field strengths, or cytokine concentrations during culture) to optimize the balance between NK cell recovery and separation efficiency. By dynamically adjusting these parameters, the process achieves complete separation from undifferentiated cells while minimizing NK cell loss.
3Reliability
If stem cells are differentiated into NK cells, then anti-tumor activity is achieved, but differentiation efficiency is low
Solution Approach 1:
The patent applies preliminary action by pre-treating stem cells with growth factors, cytokines, or culture conditions before the actual differentiation step. This preliminary preparation primes the stem cells to respond more efficiently to differentiation signals, significantly improving the differentiation efficiency and reducing the time required to generate functional NK cells with anti-tumor activity.
Solution Approach 2:
The patent implements continuous differentiation protocols where stem cells are exposed to differentiation-inducing factors continuously or in extended cycles rather than brief pulses. This continuous action maintains the differentiation drive throughout the process, preventing cell cycle arrest or dedifferentiation, and thereby improving overall differentiation efficiency and NK cell yield.
Data Source
AI summary
Methods for generating clinically safe NK cells derived from non-fully differentiated stem cells and their use in treating cancer are provided. The non-fully differentiated stem cells are co-cultured with endogenous NK cells isolated from adipocyte-containing tissue to generate a high percentage of clinically safe NK cells, where anti-tumor activity of the clinically safe NK cells in vitro is similar to that of endogenous NK cells. Optimized Production of the clinically safe autologous NK cells from stem cells provides platform for treating cancer patients by applying an effective adoptive immunotherapy ranging from the early to terminal stages.